Hormonal
GLP-1 receptor agonists (specifically semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily) produce significant weight loss in adults with obesity without diabetes, with semaglutide demonstrating superior efficacy compared to liraglutide.
For adults with obesity without diabetes, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are effective weight loss treatments. Semaglutide offers greater weight reduction than liraglutide. These drugs work by mimicking a hormone that increases satiety and slows digestion. Common side effects include gastrointestinal issues, which are often managed by starting with a lower dose and gradually increasing it.
Compared with control groups, a more significant weight loss was seen in GLP-1 RA groups with an overall mean difference of -7.1 kg... Subgroup analysis showed greater treatment effect of semaglutide than liraglutide.
Why this rating
Systematic review and meta-analysis of 12 randomized control trials with 11,459 participants.
Source
Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials
Junaid Iqbal et al. · Obesity Reviews · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →